Figure 1: Time Course of Left Ventricular Dilatation

(Upper panel) Left ventricular (LV) diastolic, LV systolic diameter, and LV fractional shortening determined, before and 90 days after sham surgery, in untreated Wistar (open circles; n = 10) and 2, 7, and 90 days after 45-min transient ischemia in placebo-treated I/R Wistar (filled circles; n = 15), early long-term (down-triangles; n = 14) or delayed long-term gevokizumab-treated I/R Wistar (up-triangles; n = 15). (Lower panel) LV diastolic, LV systolic diameter, and LV fractional shortening determined, before and 90 days after sham surgery in untreated Goto-Kakisaki (open circles; n = 12) and 2, 7, and 90 days after 20-min transient ischemia in placebo-treated I/R Goto-Kakisaki (filled circles; n = 16), early long-term (down-triangles; n = 15) or delayed long-term gevokizumab-treated I/R Goto-Kakisaki (up-triangles; n = 15). *p < 0.05 versus untreated sham. †p < 0.05 versus untreated I/R.